Table 1.
Demographic and clinical characteristics (number [percent]) of the study population by year, ANRS CO3 Aquitaine and IPEC/FIOCRUZ cohorts combined
| 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|
| Number of patients |
3911 |
4165 |
4375 |
4568 |
4898 |
5267 |
5621 |
5916 |
6144 |
| Age in yearsa |
|
|
|
|
|
|
|
|
|
| < 30 |
430 (11.0) |
419 (10.1) |
364 (8.3) |
336 (7.4) |
325 (6.6) |
384 (7.3) |
426 (7.6) |
456 (7.7) |
483 (7.9) |
| 30-39 |
1830 (46.8) |
1808 (43.4) |
1787 (40.8) |
1690 (37) |
1614 (33) |
1563 (29.7) |
1501 (26.7) |
1494 (25.3) |
1462 (23.8) |
| 40-49 |
1127 (28.8) |
1316 (31.6) |
1505 (34.4) |
1715 (37.5) |
1987 (40.6) |
2183 (41.4) |
2422 (43.1) |
2547 (43.1) |
2603 (42.4) |
| 50-59 |
359 (9.2) |
435 (10.4) |
518 (11.8) |
597 (13.1) |
700 (14.3) |
811 (15.4) |
905 (16.1) |
982 (16.6) |
1093 (17.8) |
| > = 60 |
165 (4.2) |
187 (4.5) |
201 (4.6) |
230 (5) |
272 (5.6) |
326 (6.2) |
367 (6.5) |
437 (7.4) |
503 (8.2) |
| Gender |
|
|
|
|
|
|
|
|
|
| Male |
2725 (69.7) |
2879 (69.1) |
3039 (69.5) |
3175 (69.5) |
3418 (69.8) |
3679 (69.9) |
3898 (69.3) |
4096 (69.2) |
4256 (69.3) |
| Mode of HIV transmissionb |
|
|
|
|
|
|
|
||
| Heterosexual |
1129 (28.9) |
1274 (30.6) |
1371 (31.3) |
1464 (32) |
1613 (32.9) |
1798 (34.1) |
1994 (35.5) |
2176 (36.8) |
2328 (37.9) |
| MSM |
1383 (35.4) |
1471 (35.3) |
1575 (36) |
1682 (36.8) |
1817 (37.1) |
1963 (37.3) |
2102 (37.4) |
2221 (37.5) |
2320 (37.8) |
| IDU |
1011 (25.9) |
996 (23.9) |
984 (22.5) |
955 (20.9) |
965 (19.7) |
947 (18) |
933 (16.6) |
909 (15.4) |
858 (14) |
| Other |
145 (3.7) |
150 (3.6) |
151 (3.5) |
155 (3.4) |
155 (3.2) |
157 (3) |
165 (2.9) |
161 (2.7) |
166 (2.7) |
| Unknown |
243 (6.2) |
274 (6.6) |
294 (6.7) |
312 (6.8) |
348 (7.1) |
402 (7.6) |
427 (7.6) |
449 (7.6) |
472 (7.7) |
| CD4 cell countc |
|
|
|
|
|
|
|
|
|
| > 500 |
1306 (38.3) |
1412 (39.5) |
1580 (41) |
1646 (41.9) |
1768 (40.7) |
1996 (41.9) |
2274 (44.9) |
2457 (45.3) |
2720 (47.2) |
| 351-500 |
787 (23.1) |
866 (24.2) |
920 (23.9) |
924 (23.5) |
1075 (24.7) |
1167 (24.5) |
1225 (24.2) |
1375 (25.4) |
1453 (25.2) |
| 201-350 |
777 (22.8) |
783 (21.9) |
795 (20.6) |
852 (21.7) |
931 (21.4) |
963 (20.2) |
997 (19.7) |
985 (18.2) |
1017 (17.7) |
| 51-200 |
427 (12.5) |
410 (11.5) |
449 (11.7) |
414 (10.5) |
446 (10.3) |
502 (10.5) |
459 (9.1) |
501 (9.2) |
479 (8.3) |
| <= 50 |
114 (3.3) |
107 (3) |
107 (2.8) |
94 (2.4) |
128 (2.9) |
132 (2.8) |
115 (2.3) |
103 (1.9) |
93 (1.6) |
| Plasma HIV RNAc |
|
|
|
|
|
|
|
|
|
| <= 400 |
1151 (33.8) |
1324 (37.3) |
1628 (42.3) |
1859 (47.3) |
2100 (48.8) |
2514 (53.5) |
2908 (58.5) |
3348 (63.1) |
3898 (68.4) |
| 401-3000 |
749 (22) |
795 (22.4) |
689 (17.9) |
598 (15.2) |
613 (14.3) |
604 (12.8) |
557 (11.2) |
511 (9.6) |
518 (9.1) |
| 3001-10000 |
475 (13.9) |
451 (12.7) |
445 (11.6) |
409 (10.4) |
393 (9.1) |
396 (8.4) |
345 (6.9) |
354 (6.7) |
318 (5.6) |
| 10001-100000 |
725 (21.3) |
716 (20.2) |
781 (20.3) |
789 (20.1) |
871 (20.3) |
862 (18.3) |
787 (15.8) |
805 (15.2) |
721 (12.6) |
| > 100000 |
308 (9) |
267 (7.5) |
306 (8) |
277 (7) |
323 (7.5) |
325 (6.9) |
378 (7.6) |
288 (5.4) |
246 (4.3) |
| ≤ 1 year since first HIV + testd |
|
|
|
|
|
|
|||
| Yes |
439 (11.2) |
350 (8.4) |
337 (7.7) |
316 (6.9) |
316 (6.5) |
421 (8.0) |
493 (8.8) |
496 (8.4) |
501 (8.2) |
| On cARTe |
|
|
|
|
|
|
|
|
|
| Yes |
3506 (89.6) |
3724 (89.4) |
3932 (89.9) |
4101 (89.8) |
4393 (89.7) |
4684 (88.9) |
4913 (87.4) |
5197 (87.8) |
5508 (89.6) |
| Hepatitis Bf |
|
|
|
|
|
|
|
|
|
| Yes |
215 (6.1) |
235 (6.2) |
249 (6.2) |
258 (6.1) |
280 (6.2) |
305 (6.3) |
331 (6.4) |
348 (6.4) |
367 (6.6) |
| Hepatitis Cg |
|
|
|
|
|
|
|
|
|
| Yes | 949 (26.7) | 968 (25.5) | 1013 (25.2) | 1022 (24.2) | 1027 (22.6) | 1008 (20.5) | 1018 (19.4) | 999 (18.2) | 978 (17.3) |
aAge from birth was updated yearly for each participant.
bPresumed mode of HIV exposure was classified as men who have sex with men (MSM), injection drug use (IDU), heterosexual transmission, other, and unknown.
cYearly CD4 cell counts and plasma HIV RNAs were defined as the mean value of all measurements taken in a specific calendar year.
dTime since first HIV + test was calculated for each calendar year.
eCombination antiretroviral therapy (cART) was defined as two nucleoside reverse transcriptase inhibitors plus either one non-nucleoside reverse transcriptase inhibitor or one protease-inhibitor (boosted or not).
fHepatitis B infection was defined by the presence of hepatitis B surface antigen (HBsAg).
gHepatitis C infection was defined by the presence of hepatitis C antibodies.